Advancements in Myeloma Treatment: CAR-T and Bispecific Antibodies

This chapter explores the developments in CAR-T therapy and bispecific antibodies for treating multiple myeloma, focusing on strategies for consolidation and maintenance dosing. A detailed discussion on patient experiences, clinical trial significance, and comparative effectiveness between the two therapies provides insights into treatment management and challenges. The chapter highlights the need for a diversified approach to address patient outcomes and the complexities of targeting both cancerous and normal plasma cells.